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Captopril inhibits the 72 kDa and 92 kDa matrix
metalloproteinases
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Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases.
Gelatinases are metalloproteinases in the kidney which can cleave type
IV collagen as well as gelatin. We partially purified the 72 kDa and 92
kDa gelatinases. The gelatinolytic activity was measured by zymogra-
phy and a quantitative biotin-avidin assay. By zymography, captopril in
concentrations of 20 m and 40 m added to the incubation buffer
reduced the gelatinolytic activity in a dose-dependent manner. The
addition of zinc in a concentration of 50 to 100 /SM reversed most of the
inhibitory effect of captopnl. By the biotin-avidin assay, captopril in a
concentration of 30 to 50 nM reduced half of either the 72 kDa or 92 kDa
gelatinolytic activity. Zinc in a concentration of 50 sM completely
reversed the inhibitory effect of I sM captopril on both gelatinases.
Lisinopril, a non-sulthydryl ACE inhibitor, similarly inhibited the
gelatinases, but a 1000-fold higher concentration of the drug was
needed. These findings suggest that captopril reversibly inhibits the 72
kDa and 92 kDa metalloproteinases by interacting with the zinc ion at
their active sites. This inhibitory effect is observed with captopril levels
comparable to the concentrations needed to inhibit the angiotensin
converting enzyme in vivo and may at least partially explain some of the
renoprotective effects seen with this drug.
ACE inhibitors, especially captopril, have been used to
reduce proteinuria in a variety of renal diseases [1—4] as well as
in healthy volunteers [5]. These studies have included diabetic
nephropathy with or without hypertension [6—13], hypertensive
nephropathy [14, 15], !gA nephropathy [16], membranous GN
[171, and sickle cell nephropathy [18]. Despite these numerous
studies, however, the actual mechanism for the antiproteinuric
effect of this class of antihypertensive drugs has not yet been
elucidated. A hemodynamic effect has been clearly shown by
many researchers [2—8, 10, 11, 13]. Other investigators have
proposed a mechanism by which ACE inhibitors have a primary
effect on the glomerular basement membrane permeability [9,
16, 17] or the mesangial cell metabolism [5, 17]. Clearly, the
postglomerular vasodilation observed with ACE inhibitors can
reduce the intraglomerular ultrafiltration pressure and the single
nephron filtration rate. Although it has been shown that a
reduction in glomerular ultrafiltration pressure can cause a
reduction in macromolecular clearance, the mechanism by
which this occurs has not been shown and other mechanisms by
Received for publication February 12, 1993
and in revised form July 15, 1993
Accepted for publication July 15, 1993
© 1993 by the International Society of Nephrology
which ACE inhibitors reduce proteinuria have to be considered.
Changes in the basement membrane permeability due to me-
sangial cell contraction in response to angiotensin !I, or even
charge redistribution can change glomerular permeability. ACE
inhibitors may also be "cytostatic" since angiotensin I! may
promote mesangial cell growth [19] as well as smooth muscle
cell and kidney epithelial cell proliferation [20—23]. Suppressing
the mesangial cell growth would affect the production and
metabolism of the mesangial matrix, as well as their interactions
with inflammatory cells, phagocytosis, and regulation of blood
flow. Finally, ACE inhibitors can act as antioxidants [24—28]
either by scavenging the free radicals generated directly or by
interacting with the metal ions present in their catalysts. Al-
though this effect has not yet been observed in the kidney, it
could certainly contribute to the integrity of the basement
membrane.
Collagenases are metal-dependent endopeptidases secreted
by many mesenchymal cells [29, 30]. These proteinases can
degrade both native and denatured collagen. They are usually
secreted in an inactive form and are optimally active at neutral
pH's. Zn2 is absolutely required for their activity and Ca2
may also have a role in stabilization of these proteins. There are
at least two distinct type IV collagenases with molecular masses
of 72 kDa and 92 kDa in their zymogen form [31]. Other higher
molecular weight forms are found in glomeruli [32—34] . Auto-
lytic activation after incubation with organomercurials [35—38]
or activation by treatment with other endopeptidases [36, 37]
such as trypsin, chymotrypsin, plasmin, thrombin, and cathep-
sin can then give rise to lower molecular weight products with
higher activity. This class of collagenases can degrade native
type !V, V. and V!! collagen as well as gelatin and elastin, but
not native type I collagen, proteoglycan, or fibronectin [31].
They are principally involved in matrix turnover, especially
degradation and remodeling of basement membranes. Several
studies, however, have also shown their potential role in tumor
invasion [38—40], collagen vascular disease [41, 42], liver dis-
ease [43], bone turnover [44], periodontal disease [45—47],
formation of aneurysms [48], destruction of the blood-brain
barrier [49] and glomerulonephntis [50].
!n the present study, we postulated that captopril can inhibit
the metalloproteinases secreted by the glomerular cells. This
hypothesis was based on the clinical observation that some
patients who are being treated with captopril develop a dysgeu-
sia due to Zn2 deficiency. ACE is a metalloprotease that
1266
Sorbi et a!: Captopri! inhibits metalloproteinases 1267
requires zinc to be active, just like the type IV collagenases,
and it is inhibited by ACE inhibitors such as captopril and
lisinopril, as they interact with the active center of the convert-
ing enzyme and form complexes with the zinc [51—53]. Capto-
pill is a sulfhydryl containing ACE inhibitor. Lisinopril contains
no sulfhydryl group but presumably has the same ability to
chelate zinc.
Methods
Materials
Hydrogen peroxide, ortho-phenylenediamine (OPD), and gel-
atin were obtained from Fisher Scientific (Springfield, New
Jersey, USA). Avidin DX and biotinylated horseradish perox-
idase (BHRP) were obtained from Vector Laboratories, Inc.
(Burlingame, California, USA). Biotin N-hydroxysuccinimide
ester (BNHS), RPM! 1640 with and without biotin, MEM with
D-valine, fetal bovine serum, lactalbumin hydrolysate, insulin,
transferrin, sodium selenite, streptomycin, and penicillin were
obtained from Gibco BRL (Grand Island, New York, USA).
ELISA plates (96-well modified flat bottom) were obtained from
Corning (Fairless Hill, Pennsylvania, USA). Triton X-l00,
Temed, acrylamide, and sodium dodecylsulfate were obtained
from BioRad (Melville, New York, USA). Captopril was ob-
tained from Sigma Chemical Co. (St. Louis, Missouri, USA).
Concanavalin A, Sephadex G-200 and methyl-a-D-mannoside
were obtained from Pharmacia, Inc. (Piscataway, New Jersey,
USA). Anti-Thy 1 antibody was obtained from Bioproducts for
Science (Indianapolis, Indiana, USA).
Mesangial cell culture
Primary cultures of mesangial cells were established from
collagenase-treated glomeruli recovered by passing the renal
cortex from virus-free Sprague-Dawley male rats weighing 100
to 150 g through serially graded sieves [54]. The cells were
grown in RPM! 1640 supplemented with 15% FBS, 50 U/ml
penicillin, 50 pg/mI streptomycin, 300 pg/ml glutamine, S pg/mi
bovine insulin, 5 ng/ml sodium selenite and 5 pg/ml transferrin.
Having reached confluence, they were then subcultured and
expanded to uniform colonies of interwoven, straplike cells.
The cells were characterized by positive immunostaining for
Thy 1, negative immunostaining for Factor VIII Antigen, and
growth in L-valine deficient media to which D-valine was added
[50, 54].
Enzyme purification
Confluent primary and secondary cultures were washed
extensively with RPM! 1640 without biotin and were incubated
for three to five days in the same medium containing 0.2%
lactalbumin hydrolysate [50]. The conditioned media were then
collected, centrifuged at 1000 X g for 15 minutes and the
supernatants were stored at —20°C.
Sixty milliliters of the biotin-free, serum-free conditioned
media was thawed and run at 15 mI/hr through a 30 ml Con A
column previously equilibrated with the Con A buffer (0.05 M
Tris-HCI, 10 mri CaC12, pH 7.4) at 4°C. The column was then
washed with 150 ml of the same buffer to elute the 72 kDa
collagenase and with 150 ml of 0.3 M a-D-mannoside in Con A
buffer to elute the 92 kDa gelatinase [40]. After extensive
dialysis against the column buffer for the G-200 column (0.05 M
Tris-HCI, 0.2 M NaCI, 5 mM CaCI2, pH 7.4), the 72 kDa and 92
kDa rich washings were concentrated using polyethylene gly-
col. A 2.5 cm x 95 cm G-200 column was equilibrated at 4°C
with its buffer and calibrated [40]. Five milliliters of either the
72 or 92 kDa concentrate was then applied to the column and
four ml fractions were collected at 3 mI/cm2 hr. The gelatinase
activity of every second fraction was determined by the gelatin-
substrate biotin-avidin assay and was confirmed by zymogra-
phy using gelatin-substrate SDS-PAGE electrophoresis. The
absorbance at 280 nm was also measured.
Enzyme assay
Zymography. SDS-PAGE electrophoresis [55] was per-
formed on vertical slab gel containing 7.5% acrylamide and 0.25
mg/mi gelatin under nonreducing conditions at 4°C. After ex-
tensive washing with at least 500 ml of 2.5% Triton X over one
hour, the gels were incubated overnight at 37°C in the collagen
assay buffer (0.05 M Tris-HCI, 0.2 M NaCl, 10 mi CaCI2, pH
7.4) to which captopril with or without zinc was added for the
inhibition studies. For visualization of the gelatinolytic bands,
the gels were stained for two hours in 0.1% Coomassie Brilliant
Blue (50% methanol, 10% acetic acid, and 0.1% Coomassie
Blue in dH2O) and destained for five minutes with destain (20%
methanol and 10% acetic acid in dH2O).
Biotin-avidin assay. A non-radioactive assay for type IV
collagen degradation as described by Wilkinson, Cohen and
Shuman [56] was employed and modified by us to allow the use
of gelatin as substrate. Gelatin (1 mg/mI in distilled water) was
dialyzed overnight against 0.1 M sodium bicarbonate at 4°C.
Biotin n-hydroxysuccinimide ester (BNHS) was dissolved in
dimethylsulfoxide (DMSO) to a final concentration of 1 mg/mI
and was allowed to react with the gelatin for four hours at 4°C
(0.25 mg Biotin NHS per 1 mg gelatin). The biotinylated gelatin
was then extensively dialyzed against phosphate-buffered saline
(PBS), pH 7.4, and aliquots of 0.5 mg were stored at —20°C.
Two 96-well modified flat bottom ELISA plates were coated
overnight with avidin (100 p1 of 10 pg/mI in distilled water per
well) and blocked with 0.3% bovine serum albumin (BSA) in
PBS. Biotinylated gelatin was diluted to 50 pg/mI and 100 1.d
was added to each well of one of the avidin-coated ELISA
plates. After incubation for one hour at 20°C, this plate was
rinsed with PBS. The collagenase samples were diluted in the
enzyme buffer (150 mri NaCl, 50 m Iris, 10 mti CaCI2, pH
7.4) and then incubated with captopril or lisinopril in the
presence or absence of excess zinc for one hour at 37°C before
addition to the gelatin coated plate. Following three hours of
incubation at 37°C, the supernatants from the first plate were
transferred to the second avidin-coated ELISA plate and incu-
bated for 30 minutes at 20°C. The second plate was washed
twice with PBS prior to incubation with biotinylated horserad-
ish peroxidase (1:16000 BHRP in dH2O), for 30 minutes. The
o-phenylenediamine (OPD) substrate (50 ml dH2O, 5 p1 30%
H202, 500 p110 mg/mI OPD in methanol) was added following
rinsing of the plate and the reaction was stopped after incuba-
tion in the dark for 30 minutes at 20°C by the addition of 4 M
H2S04. The optical density was then read at 490 nm.
Results
To be able to quantitate the gelatinolytic activity and to
assess the plate-to-plate reproducibility of the biotin-avidin
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Fig. 1. Optical densities corresponding to known amounts of gelatin
degraded. In the range shown, straight lines with a correlation coeffi-
cient of 0.99 0.01 were obtained. Number of determinations 8.
assay, known dilutions of the biotinylated gelatin were added
directly to the second avidin-coated plate in a repetitive manner
(Fig. 1). After incubation with BHRP and addition of the
OPD-substrate, the reaction was stopped as usual, and the
optical density was determined and plotted against the nano-
grams of gelatin added. The change in optical density with
respect to the change in gelatin concentration was linear from
zero to 550 ng yielding the following equation: (ng biotinylated
gelatin degraded/3 hours)= —0.232 0.010 X (optical density at
490 nm) + 536.5 15.6 with a correlation coefficient of 0.99
0.01. On a single plate, the optical density of any dilution varied
by less than 5% of its mean absorbance at 490 nm.
The effect of captopnl, in the presence or absence of Zn2,
on the gelatinolytic activity of the metalloproteinases is shown
by zymography in Figures 2 and 3. There are three main
gelatinolytic bands with the relative molecular weights of 66
kDa, 68 kDa, and 88 kDa. We feel these correspond with
previously described 72 kDa and 92 kDa bands [50, 57, 58].
Captopril added to the collagenase incubation buffer in a
concentration of 20 m and 40 ifiM decreased the activity of the
gelatinases present (Fig. 2) in a concentration-dependent fash-
ion. By zymography, the inhibitory effect of captopril was
greater on the 72 kDa than on the 92 kDa gelatinase. This might
not reflect the real inhibitory capacity of captopril because high
concentrations are needed to penetrate the polyacrylamide-
gelatin complex to reach the gelatinases. Furthermore, changes
in the configuration of the metalloproteinases inside the gel
matrix can make them more or less susceptible to inhibition.
We hypothesized that the inhibitory action of captopril re-
sides in the ability of this compound to chelate Zn2 at the
active site of the metalloproteinases. To confirm this, we
repeated the above experiments with the 72 kDa and 92 kDa
gelatinases (Fig. 3; lanes A and B). Captopnl, in a concentration
of 20 mM added to the incubation buffer (lanes C and D),
Discussion
Type IV collagenases are involved in the remodeling of the
extracellular matrix and our results indicate that captopril can
inhibit both the 72 kDa and 92 kDa gelatinases. Many glomer-
ular cells can produce these gelatinases and they can be
involved in the normal physiological turnover of the basement
membrane [50, 57]. In pathological states, however, cytokines,
growth factors, immune complexes, and complement [30] could
enhance the expression of these metalloproteinases and cause
the disruption of the basement membrane. ACE inhibitors, by
inhibiting these collagenases, could have a protective effect by
preserving the integrity of the basement membrane and delay-
ing or even preventing the development of proteinuria.
The inhibitory effect of captopril on both the 72 kDa and the
92 kDa collagenases was comparable when biotinylated gelatin
was used as substrate. By the biotin-avidin assay, statistically
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inhibited both gelatinases as already described. The presence of
excess zinc in a concentration of 50 to 100 LM (lanes E to H)
completely reversed the inhibition. Higher concentrations of
zinc (1000 SM), however, further increased the inhibitory effect
of 20 LM captopnl (lanes I and J).
By zymography, captopril inhibited the gelatinolytic activity
of purified gelatinases at a concentration of 20 to 40 m. Using
a modified biotin-avidin assay for measuring gelatinolytic activ-
ity, concentrations of the 92 and 72 kDa gelatinases in enzyme
buffer were used that gave rise to the degradation of 300 to 500
ng gelatin over three hours. The 92 kDa gelatinase required no
activation, whereas the 72 kDa collagenase required prior
incubation with 0.5 mri APMA at room temperature for one
hour. The optical densities corresponding to known amounts of
degraded biotinylated gelatin were fit to a straight line with an
absolute correlation coefficient of 0.99 0.01 in the range of 0
to 550 ng gelatin as already described. The dose-dependent
inhibitory effect of captopril is shown in Figure 4. The open
circles represent the 92 kDa and the closed circles represent the0 100 200 300 400 500 600 72 kDa collagenase. From this plot of relative activity versus
captopril concentration, a captopril concentration of about 30 to
50 flM is required to inhibit 50% of the gelatinolytic activity of
either the 72 kDa or 92 kDa collagenase when biotinylated
gelatin is used as substrate.
To observe the potential role of the suithydryl group, lisino-
pril, a non-sulihydryl ACE inhibitor, was also tested. Like
captopril, lisinopril is not a prodrug and should be active in
vitro. Unlike captopril, however, it may be a more selective
ACE inhibitor, is longer acting, and is much less commonly
associated with taste abnormalities. As shown in Figure 5,
lisinopril can also inhibit these gelatinases although about
1000-fold higher concentrations are needed to achieve the same
degree of inhibition. Further studies are needed to compare the
potencies of different ACE inhibitors.
Finally, to see if the action of captopril was being mediated
via the chelation of Zn2, we measured the 72 and 92 kDa
gelatinolytic activity by the biotin-avidin assay in the presence
of vehicle, captopril 1 captopril 1 M plus Zn2 50 M (Fig.
6 A and B), and 50 M zinc. There was complete inhibition of
both collagenases by 1 M captopril. Furthermore, there was
100% reversal of the inhibitory effect of 1 LMcaptopril in the
presence of 50 p zinc (P < 0.01). Zinc alone had no statisti-
cally significant effect on the activity of either enzyme.
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significant (P 0.05) levels of inhibition were observed when
the 72 kDa and 92 kDa metalloproteinases were incubated with
at least 0.01 M and 0.1 M captopril, respectively. The
reversal of the inhibitory effect by Zn2 in a concentration of 50
jsM was especially manifest with captopril in a concentration of
0.1 to 1 M.
Based on the observation that captopril can inhibit type IV
collagenases and that this inhibition can be reversed by the
Fig. 2. SDS-PAGE gelatin-substrate
zymography showing the inhibitory effect of
captopri!. Lanes A and B: purified 92 kDa and
72 kDa gelatinases incubated in assay buffer
containing no captopril, respectively. Lanes C
and D: assay buffer containing 20 mi
captopnl. Lanes E and F: assay buffer
containing 40 mi captopril. By zymography,
captopril inhibits both gelatinases in a dose-
dependent manner.
Fig. 3. SDS-PAGE gelatin-substrate
zymography showing the effect of captopril in
the presence of excess zinc. Lanes A and B:
purified 92 kDa and 72 kDa gelatinases
incubated in assay buffer containing no
captopril, respectively. Lanes C and D: assay
buffer containing 20 mi captopril. Lanes E
and F: assay buffer containing 20 mi
captopnl and 50 M zinc. Lanes 0 and H:
assay buffer containing 20 mr.i captopril and
100 LM zinc. Lanes I and J: assay buffer
containing 20 mM captopril and 1000 ILM zinc.
Zinc, in a concentration of 50 to 100 LM, can
fully reverse the inhibitory action of 20 mai
captopnl on the 92 and 72 kDa gelatinases.
presence of excess Zn2, the most plausible explanation for its
mode of action would be the chelation of Zn2 at the active site.
This is compatible with the data that other metal chelators such
as EDTA and 1,10 phenanthroline are potent inhibitors of
metalloproteinases.
Several studies refer to the antioxidant ability of ACE inhib-
itors [24—28]. Certainly, thiol groups can react with free radi-
cals. Jay, Zamorano and Cuellar [26] however, believe that the
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Fig. 4. Effect of captopril on the activity of the 92 kDa (open circles)
and 72 kDa gelatinases (closed circles) measured by the biotin-avidin
assay. Captopnl concentrations of 30 to 50 nM are sufficient to reduce
the gelatinolytic activity of either enzyme by half. Number of determi-
nations = 8 for 92 kDa, 4 for 72 kDa.
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Fig. 6. Reversal of the inhibitory effect of I Mcaptopril on the 92 kDa
(A) and 72 kDa (B) gelatinases by 50 sw zinc (*P <0.01). Zinc alone had
no statistically significant effect on the activity. Number of determina-
0.001 0.01 0.1 1 10 100 tions = 8.
Fig. 5. Effect of lisinopril on the gelatinolytic activity of the 92 kDa
(open circles) and 72 kDa (closed circles) metalloproteinases as deter-
mined by the biotin-avidin assay. Lisinopril can inhibit these gelati-
nases, although 10 to 100 M concentrations, that is, 1000-fold higher
concentrations than with captopril, were needed. Number of determi-
nations = 8 for 92 kDa, 4 for 72 kDa.
antioxidant effect may be mediated through the chelation of
divalent ions such as Cu2, as demonstrated by the inhibition of
the aerobic Cu2-initiated autooxidation of phenyihydrazine by
captopril. Finally, many investigators have demonstrated that
free cysteine, acetylcysteine, f3-mercaptomethyl-tripeptides,
and sulthydryl-based substrate analogues can all inhibit colla-
genases [59—66]. Using a synthetic substrate containing a suif-
hydryl group, Burns et al [64] found that at a concentration of 10
flM it reduces the activity of a collagenase isolated from
alkali-burned rabbit cornea by 50%. A similar N-carboxyalkyl
tripeptide was much less active requiring a 25 pM concentration
for the same degree of inhibition, demonstrating the significance
of the sulthydryl group. Schwartz et al [65] have observed
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comparable degrees of inhibition with mercaptans derived from
HS-(CH2-R-Leu)-derivative, with HS-(CH2-R-Leu)Phe-AIa-
NH2 in a concentration of 42 flM inhibiting 50% of the human
neutrophil collagenase activity. Captopril is a dipeptide ana-
logue containing L-proline and a D-3-mercapto-methylpro-
panoyl group. The sulfhydryl group can readily chelate Zn2 as
the rest of the molecule interacts with the amino acids of the
active site. This is the presumed mechanism of action of the
suithydryl-containing inhibitors mentioned above and as our
results indicate, also appears to be the mechanism for the
inhibitory effect of captopril on the collagenases studied. The
significance of the sulfhydryl group of captopril in inhibiting the
gelatinase activity is confirmed by our findings that almost
1000-fold higher concentrations of lisinopril are needed to
observe the same degree of inhibition.
The 72 kDa and 92 kDa gelatinases were isolated from
primary and secondary mesangial cell cultures, Although me-
sangial cells have been shown to produce the 72 kDa type IV
collagenase [50, 57, 58] the source of the 92 kDa gelatinase is
not clear. The 92 kDa metalloprotease is no longer present after
the fifth passage. Contamination by other glomerular cells is
possible. Furthermore, previous investigators have failed to
demonstrate the transcription of the 92 kDa gelatinase in
mesangial cells by cDNA probes [33]. No matter what its origin,
however, the 92 kDa collagenase was readily inhibited by
captopril levels that can be easily achieved in serum or in the
glomerular matrix by a daily oral dose of less than 100 mg/day
[51, 67].
In summary, captopril in concentrations comparable to those
required to inhibit the angiotensin converting enzyme readily
inhibits matrix metalloproteinases which can degrade type IV
collagen and damage the glomerular basement membrane. This
inhibitory effect of captopril on collagenases may partially
explain the reduction in proteinuria observed with this class of
antihypertensive drugs.
Reprint requests to Leonard Arbeit, M.D., Division of Nephrology
and Hypertension, SUNY at Stony Brook, Stony Brook, New York
11794, USA.
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